Duloxetine Capsule, Delayed Release
Product Images NDC 71205-358

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71205-358). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure01 (Duloxetine Fig01)

A Kaplan-Meier plot depicting the proportion of patients with relapse over time measured in days from randomization. The graph compares Duloxetine treatment, represented by a solid line, to placebo, shown as a dashed line, illustrating relapse rates up to 200 days.*

FDA Label Image

Figure2 (Duloxetine Fig02)

A Kaplan-Meier curve graph comparing the proportion of patients with relapse over time in days from randomization, for two treatments: placebo (dashed line) and duloxetine (solid line). The graph shows relapse proportion on the vertical axis and time in days on the horizontal axis up to 300 days.*

FDA Label Image

Figure04 (Duloxetine Fig04)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The x-axis shows percent improvement in pain from baseline (0 to 100%), and the y-axis shows the percentage of patients improved (0 to 70%). Duloxetine groups show higher percentages of patient improvement compared to placebo across the pain improvement scale.*

FDA Label Image

Figure07 (Duloxetine Fig07)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis shows percent improvement in pain from greater than 0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100%. Two curves depict the data, with Duloxetine consistently showing higher patient improvement percentages across the pain improvement spectrum compared to placebo.*

FDA Label Image

Figure08 (Duloxetine Fig08)

A line graph comparing the percentage of patients improved by Duloxetine 60 mg once daily versus placebo across various levels of percent improvement in pain from baseline. The x-axis shows percent improvement in pain from >0% to 100%, and the y-axis shows the percentage of patients improved from 0 to 100%. Duloxetine data points are represented by solid diamonds, showing a higher percentage of patients improved at most pain improvement intervals compared to placebo, which is represented by x marks with a dashed line.*

FDA Label Image

Figure09 (Duloxetine Fig09)

A line graph comparing the percentage of patients improved by placebo versus Duloxetine 60/120 mg once daily, across different levels of percent improvement in pain from baseline (BOCF). The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Two lines with markers depict patient response rates for placebo and Duloxetine treatments.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride, showing a naphthalene group connected to a propylamine side chain with a thiophene ring, including the hydrochloride salt form.*

FDA Label Image

71205-358-30 (Duloxetine 60mg)

Label for Duloxetine 60 mg delayed-release capsules from Proficient Rx LP. The label states the package contains 30 capsules, each with enteric-coated pellets equivalent to 60 mg duloxetine. It includes storage instructions, product ID, marketing by Ajanta Pharma USA Inc., and notes the capsules are white with blue color cap imprinted with "DLX60" and "ap." The label also shows NDC 71205-358-30 and indicates prescription only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.